India's drug regulator reportedly seeks answers about unapproved drugs in national formulary

The Economic Times reports that India's drug regulator asked the Indian Pharmacopoeia Commission why the 2026 National Formulary of India included drugs lacking CDSCO approval. The paper identified at least five drugs or variants without approval. A commission official said it had made its best possible efforts to exclude unapproved drugs. The regulator separately called the online edition's unavailability a “serious concern” after stakeholder complaints.